

FILE 'REGISTRY' ENTERED AT 11:34:03 ON 26 MAR 2008

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 0 S L2
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 STRUCTURE UPLOADED
L7 0 S L6
L8 0 S L6 SSS FULL
L9 STRUCTURE UPLOADED
L10 1 S L9
L11 8 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:46:02 ON 26 MAR 2008

L12 5 S L11

FILE 'HCAPLUS' ENTERED AT 11:47:35 ON 26 MAR 2008

L13 36385 S REVERSE TRANSCRIPTASE
L14 1852 S NON-NUCLEOSIDE
L15 257556 S UREA OR THIOUREA
L16 13764 S CYCLOPROPYL
L17 72 S L13 AND L14 AND L15
L18 3 S L13 AND L14 AND L15 AND L16
L19 45 S L17 AND (PY<2003 OR AY<2003 OR PRY<2003)
L20 3 S L18 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:34:03 ON 26 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAR 2008 HIGHEST RN 1010115-69-1
DICTIONARY FILE UPDATES: 25 MAR 2008 HIGHEST RN 1010115-69-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10526598structure.str



```

chain nodes :
18 19 20 22 23 25 31 33 34 35 40 41 42
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 26 27 28 29 30
chain bonds :
7-42 8-41 9-18 9-40 18-19 18-23 19-20 19-22 20-25 20-26 29-33 31-33
31-34
34-35
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-10 6-8 7-9 7-8 7-12 8-9 10-11 11-12 26-27
26-30 27-28 28-29 29-30
exact/norm bonds :
5-6 5-10 6-8 7-9 7-8 7-12 7-42 8-9 8-41 9-18 9-40 10-11 11-12 18-19
18-23 19-20 19-22 20-25 20-26 26-27 26-30 27-28 28-29 29-30 29-33 31-33
31-34 34-35

normalized bonds :
1-2 1-6 2-3 3-4 4-5

```

G1:C,O,S,N

G2:O,S

G3:H,CH3,Et,n-Pr,i-Pr

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 18:CLASS 19:CLASS 20:CLASS 22:CLASS 23:CLASS 25:CLASS
 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 33:CLASS 34:CLASS 35:Atom 40:CLASS 41:CLASS
 42:CLASS

Generic attributes :

35:

Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED



=> s l1

STRUCTURE TOO LARGE - SEARCH ENDED

A structure in your query is too large. You may delete attributes or atoms to reduce the size of the structure and try again.

=>

Uploading C:\Program Files\Stnexp\Queries\10526598str2.str



chain nodes :

18 19 20 22 23 25 31 33 34 35 40 41 42

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 26 27 28 29 30

7-42 8-41 9-18 9-40 18-19 18-23 19-20 19-22 20-25 20-26 29-33 31-33
31-34
34-35

1-2 1-6 2-3 3-4 4-5 5-6 5-10 6-8 7-9 7-8 7-12 8-9 10-11 11-12 26-27
26-30 27-28 28-29 29-30

5-6 5-10 6-8 7-9 7-8 7-12 7-42 8-9 8-41 9-18 9-40 10-11 11-12 18-19
18-23 19-20 19-22 20-25 20-26 26-27 26-30 27-28 28-29 29-30 29-33 31-33
31-34 34-35

1-2 1-6 2-3 3-4 4-5

G2:0, S

G3 : H, CH₃, Et, n-Pr, i-Pr

```

1:Atom    2:Atom    3:Atom    4:Atom    5:Atom    6:Atom    7:Atom    8:Atom    9:Atom    10:Atom
11:Atom   12:Atom   18:CLASS  19:CLASS  20:CLASS  22:CLASS  23:CLASS  25:CLASS
26:Atom   27:Atom   28:Atom
29:Atom   30:Atom   31:Atom   33:CLASS  34:CLASS  35:Atom   40:CLASS  41:CLASS
42:CLASS

```


35:

Type of Ring System : Monocyclic

```
L2      STRUCTURE  UPLOADED
```

L2 HAS NO ANSWERS

L2 STR



G2 O, S

G3 H, Me, Et, n-Pr, i-Pr

Structure attributes must be viewed using STN Express query preparation.

=> s 12

SAMPLE SEARCH INITIATED 11:35:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 223 TO ITERATE

100.0% PROCESSED 223 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**



PROJECTED ITERATIONS: 3565 TO 5355

PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L2

=>

Uploading C:\Program Files\Stnexp\Queries\10526598str3.str



chain nodes :

18 19 20 22 23 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :
7-31 8-30 9-18 9-29 18-19 18-23 19-20 19-22 20-25 20-26 26-27 26-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-10 6-8 7-9 7-8 7-12 8-9 10-11 11-12
exact/norm bonds :
5-6 5-10 6-8 7-9 7-8 7-12 7-31 8-9 8-30 9-18 9-29 10-11 11-12 18-19
18-23 19-20 19-22 20-25 20-26 26-27 26-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5

G1:C,O,S,N

G2:O,S

G3:H,CH3,Et,n-Pr,i-Pr

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 18:CLASS 19:CLASS 20:CLASS 22:CLASS 23:CLASS 25:CLASS
26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS 31:CLASS

L4 STRUCTURE UPLOADED

=> s 14

SAMPLE SEARCH INITIATED 11:36:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 68 TO 532


PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 C, O, S, N


G2 O, S

G3 H, Me, Et, n-Pr, i-Pr

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10526598str4.str




```

chain nodes :
10 11 12 14 15 16 17 18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-8 7-21 8-20 9-10 9-19 10-11 10-15 11-12 11-14 12-16 16-17 16-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-9 7-8 8-9
exact/norm bonds :
7-9 7-8 8-9 9-10 10-11 11-12 11-14 12-16 16-17 16-18
exact bonds :
6-8 7-21 8-20 9-19 10-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G2:O,S

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS

```

L6 STRUCTURE UPLOADED

=> s 16

SAMPLE SEARCH INITIATED 11:37:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH  **COMPLETE**

```

PROJECTED ITERATIONS: 1 TO 80


PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> d 17


L7 HAS NO ANSWERS

L6 STR



G1

G2 O,S



```

chain nodes :
1  5  6  7  9  10  11  12  13  14
ring nodes :
2  3  4
chain bonds :
1-3  2-13  2-14  3-12  4-5  4-11  5-6  5-10  6-7  6-9
ring bonds :
2-4  2-3  3-4
exact/norm bonds :
2-4  2-3  3-4  4-5  5-6  6-7  6-9
exact bonds :
1-3  2-13  2-14  3-12  4-11  5-10

```

G2:O,S

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:CLASS  6:CLASS  7:CLASS  9:CLASS  10:CLASS
11:CLASS

```

12:CLASS 13:CLASS 14:CLASS

L9 STRUCTURE UPLOADED

=> s 19

SAMPLE SEARCH INITIATED 11:45:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 680 TO ITERATE

100.0% PROCESSED 680 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 12036 TO 15164

PROJECTED ANSWERS: 1 TO 80

L10 1 SEA SSS SAM L9

=> d 110 scan


L10 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 2-Propenamide, N-[[[(1 α ,2 α ,3 α)-2,3-bis[(phenylmethoxy)methyl]cyclopropyl]amino]carbonyl]-3-methoxy-2-methyl-(9CI)

MF C25 H30 N2 O5

Relative stereochemistry.

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 19 sss full

FULL SEARCH INITIATED 11:45:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 12485 TO ITERATE

100.0% PROCESSED 12485 ITERATIONS

8 ANSWERS


SEARCH TIME: 00.00.01

L11 8 SEA SSS FUL L9

=> d 111 scan

L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Propenamide, N-[[[2,3-bis[(phenylmethoxy)methyl]cyclopropyl]amino]carbonyl]-3-methoxy-2-methyl-, (1 α ,2 α ,3 β)- (9CI)
 MF C25 H30 N2 O5

Relative stereochemistry.
 Double bond geometry unknown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):7

L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Propenamide, N-[[[(1 α ,2 α ,3 α)-2,3-bis[(phenylmethoxy)methyl]cyclopropyl]amino]carbonyl]-3-methoxy-2-methyl- (9CI)
 MF C25 H30 N2 O5


Relative stereochemistry.
 Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Urea, [2,3-bis[(phenylmethoxy)methyl]cyclopropyl]-, (1 α ,2 α ,3 β)- (9CI)
 MF C20 H24 N2 O3


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Urea, [2,3-bis[(phenylmethoxy)methyl]cyclopropyl]-,
 (1 α ,2 β ,3 β)- (9CI)
 MF C20 H24 N2 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Urea, (2-ethenyl-3-methylcyclopropyl)- (9CI)
 MF C7 H12 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Urea, [2,3-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]cyclopropyl]-,
 (1 α ,2 α ,3 β)- (9CI)
 MF C18 H40 N2 O3 Si2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Propenamide, N-[[[2,3-bis[(phenylmethoxy)methyl]cyclopropyl]amino]carbon
 yl]-3-methoxy-2-methyl-, (1 α ,2 β ,3 β)- (9CI)
 MF C25 H30 N2 O5


Relative stereochemistry.
 Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 8 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Propenamide, N-[[[2,3-bis[(phenylmethoxy)methyl]cyclopropyl]amino]carbon
 yl]-3-methoxy-2-methyl-, [1 α (E),2 α ,3 β]- (9CI)
 MF C25 H30 N2 O5

Relative stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file cpalus

'CPALUS' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

359.94

360.15

FILE 'CAPLUS' ENTERED AT 11:46:02 ON 26 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Mar 2008 VOL 148 ISS 13

FILE LAST UPDATED: 25 Mar 2008 (20080325/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l11

L12 5 L11

=> d l12 1-5 ti abs bib

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

TI Novel preparation of cis,cis-trisubstituted cyclopropane nucleosides

AB Novel cyclopropane nucleosides, cis-2',cis-3'-bis(hydroxymethyl)cyclopropyl thymine and adenine were synthesized. The stereoselective ring contraction of cyclobutyl bromohydrin afforded a cyclopropyl aldehyde with a cis,cis configuration. After oxidation, conversion to amide and Hofmann's rearrangement, the Me carbamate was obtained. Its basic hydrolysis yielded an amine, then the target mols. were obtained by construction of bases.

AN 1999:100564 CAPLUS <<LOGINID::20080326>>

DN 130:196913


TI Novel preparation of cis,cis-trisubstituted cyclopropane nucleosides

AU Gauvry, Noelle; Huet, Francois

CS Laboratoire de Synthese Organique, UPRES A CNRS 6011, Faculte des
 Sciences, Universite di Maine, Le Mans, F-72085, Fr.
 SO Tetrahedron (1999), 55(5), 1321-1328
 CODEN: TETRAB; ISSN: 0040-4020
 PB Elsevier Science Ltd.
 DT Journal
 LA English

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of cyclopropane ring-containing nucleic acid bases as
 antiviral, antitumor, and antibacterial agents
 GI



AB Cyclopropane carbocyclic nucleosides (I; 1 of R1, R2 = H, the other =
 CH2OR4; R3, R4 = H, phenylalkyl; R5 = Q-Q3; R6 = alkyl; X1 = halo; R7 =
 halo, amino) are prepared as antiviral, antitumor, and antibacterial agents
 (no data). Thus, heating a solution of 272 mg I (R1 = PhCH2OCH2, R2 = H, R3
 = CH2Ph, R5 = NHCONHCOCMe:CHOMe) and NH3 in MeOH at 85° in a sealed
 tube for 23 h gave 163 mg I (R1 = PhCH2OCH2, R2 = H, R3 = CH2Ph, R5 = Q,
 R6 = Me) (II) and 37 mg I (R1 = PhCH2OCH2, R2 = H, R3 = CH2Ph, R5 = Q3).
 Treatment of 340 mg II with BF3 in CH2Cl2 at -78° to room temperature
 gave 154 mg I (R1 = HOCH2, R2 = H, R3 = H, R5 = Q, R6 = Me).

AN 1992:470271 CAPLUS <<LOGINID::20080326>>

DN 117:70271

TI Preparation of cyclopropane ring-containing nucleic acid bases as
 antiviral, antitumor, and antibacterial agents

IN Kaneko, Shuetsu; Katagiri, Shinya

PA Otsuka Seiyaku K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04074169	A	19920309	JP 1990-188647	19900716
PRAI	JP 1990-188647		19900716		
OS	MARPAT 117:70271				

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of cyclopropyl nucleoside analogs with antiviral activity
 GI



AB Title compds. [I; A = purin-9-yl, pyrimidin-1-yl, or their isosteres; G,D = H, (un)substituted C1-10 alkyl, OH, CHO, CO₂R₁, OCH₂PO₃H₂; R₁ = H, C1-10 alkyl; provided that one of D or G is other than H or C1-10 alkyl] are prepared Thus, a mixture of 2-(1,2-dihydroxyethyl)cyclopropylamine (preparation given), 2-amino-4,6-dichlorpyrimidine, Et₃N, and n-BuOH was refluxed 4 h with stirring to give 47% 1-[(2-amino-6-chloropyrimidin-4-yl)amino]-2-(1,2-dihydroxyethyl)cyclopropane. This was coupled with p-chlorobenzenediazonium chloride in aqueous NaOAc-AcOH buffer to give 65% a diazo compound which was reduced with Zn/AcOH at 70° to give 1-[(2,5-diamino-6-chloropyrimidin-4-yl)amino]-2-(1,2-dihydroxyethyl)cyclopropane. The latter was stirred 72 h at room temperature with HC(OEt)₃ in DMF containing concentrated H₂SO₄ and the resulting 6-chloropurine derivative was hydrolyzed with 2 N aqueous HCl under reflux to give 9-[2-(1,2-dihydroxyethyl)cyclopropyl]guanine (II). II in vitro showed a virus rating of 1.8 and at 101 µg/mL gave 50% inhibition of virus-induced cytopathogenic effects in E-377 cells challenged with herpes simplex virus.


AN 1991:450218 CAPLUS <<LOGINID::20080326>>
 DN 115:50218
 TI Preparation of cyclopropyl nucleoside analogs with antiviral activity
 IN Norbeck, Daniel W.; Rosen, Terry J.; Sham, Hing L.
 PA Abbott Laboratories, USA
 SO U.S., 22 pp.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4988703	A	19910129	US 1989-355594	19890522
PRAI	US 1989-355594		19890522		
OS	MARPAT 115:50218				

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Synthesis of nucleosides and related compounds. Part 20. Synthesis of 9-(t-2,c-3-dihydroxymethyl-r-1-cyclopropyl)-9H-adenine (a lower methylene homolog of carbocyclic oxetanocin) and related compounds
 GI



AB To clarify the relationship of side chain conformation and flexibility to biol. activity, a series of carbocyclic analogs of oxetanocin having a one-methylene unit shorter in the cyclobutane ring, 9-(t-2,c-3-dihydroxymethyl-r-1-cyclopropyl)-9H-adenine (I) and the related compds. II-IV were synthesized.

AN 1991:122948 CAPLUS <<LOGINID::20080326>>

DN 114:122948

TI Synthesis of nucleosides and related compounds. Part 20. Synthesis of 9-(t-2,c-3-dihydroxymethyl-r-1-cyclopropyl)-9H-adenine (a lower methylene homolog of carbocyclic oxetanocin) and related compounds

AU Katagiri, Nobuya; Sato, Hiroshi; Kaneko, Chikara

CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan

SO Chemical & Pharmaceutical Bulletin (1990), 38(11), 3184-6
CODEN: CPBTAL; ISSN: 0009-2363


DT Journal

LA English

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

TI The diazo route to 2-vinylcyclopropylidenes

GI



AB Propylidenes I (R = H, Me; R1 = vinyl, CH:CD2, CH:CHMe) were generated via N2CHCO2Et addition to alkadienes or α,β -unsatd. aldehydes. Wittig reaction of the aldehyde moiety yielded substituted

cyclopropanecarboxylates. Hydrolysis, Curtius degradation, and nitrosation produced due nitrosoureas, which formed I upon addition of base. In MeOH and NaHCO₃ I yielded the ring-opened methoxypentadienes. In MeOH-NaOMe the carbene generated from I underwent allene formation and Skattebol rearrangement (L. Skattebol, 1962) competitively. Methoxycyclopentenones occurred in excess over cyclopentadienes. In the presence of CH₂:CHOMe, I ring expanded to the cyclopentene carbene, which cycloadded to generate the spiro compds. or underwent electrophilic addition

AN 1986:68476 CAPLUS <<LOGINID::20080326>>
 DN 104:68476
 OREF 104:10949a,10952a
 TI The diazo route to 2-vinylcyclopropylidenes
 AU Kirmse, Wolfgang; Van Chiem, Pham; Henning, Paul Georg
 CS Abt. Chem., Ruhr-Univ., Bochum, 4630, Fed. Rep. Ger.
 SO Tetrahedron (1985), 41(8), 1441-51
 CODEN: TETRAB; ISSN: 0040-4020
 DT Journal
 LA English
 OS CASREACT 104:68476

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.03	375.18
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

FILE 'STNGUIDE' ENTERED AT 11:46:24 ON 26 MAR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 21, 2008 (20080321/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	375.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

FILE 'HCAPLUS' ENTERED AT 11:47:35 ON 26 MAR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Mar 2008 VOL 148 ISS 13
FILE LAST UPDATED: 25 Mar 2008 (20080325/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s reverse transcriptase

```
          242046 REVERSE
          36995 TRANSCRIPTASE
L13       36385 REVERSE TRANSCRIPTASE
          (REVERSE(W)TRANSCRIPTASE)
```

=> s non-nucleoside

```
          950092 NON
          49897 NUCLEOSIDE
L14       1852 NON-NUCLEOSIDE
          (NON(W)NUCLEOSIDE)
```

=> s urea or thiourea

```
          223626 UREA
          44764 THIOUREA
L15       257556 UREA OR THIOUREA
```

=> s cyclopropyl

```
L16       13764 CYCLOPROPYL
```

=> s l13 and l14 and l15

```
L17       72 L13 AND L14 AND L15
```

=> s l13 and l14 and l15 and l16

```
L18       3 L13 AND L14 AND L15 AND L16
```

=> s l17 and (PY<2003 or AY<2003 or PRY<2003)

```
          22929602 PY<2003
          4479974 AY<2003
          3955297 PRY<2003
L19       45 L17 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> s l18 and (PY<2003 or AY<2003 or PRY<2003)

```
          22929602 PY<2003
          4479974 AY<2003
          3955297 PRY<2003
L20       3 L18 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	377.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

FILE 'STNGUIDE' ENTERED AT 11:47:47 ON 26 MAR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Mar 21, 2008 (20080321/UP).



=> d l20 1-3 ti abs bib
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L20 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of amino acid-containing non-nucleoside
 reverse transcriptase inhibitors
 AB Non-nucleoside reverse transcriptase
 inhibitors Rx-L*-O-Ar1-CHR4CHR5NHC(:Z)NH-Ar2 [Ar1 is an unsatd.,
 optionally substituted, mono- or bicyclic ring structure comprising 0-3
 hetero atoms selected from S, O and N; Ar2 is an aromatic, optionally
 substituted, monocyclic ring structure comprising at least one nitrogen
 hetero atom and 0-2 further hetero atoms selected from S, O and N; R4, R5
 = H, (cyclo)alkyl, alkenyl, alkynyl, alkoxy, alkanoyloxy, alkylthio,
 amino, carboxy, carbamoyl, cyano, halo, hydroxy, aminomethyl,
 hydroxymethyl, carboxymethyl, haloalkylthio, nitro; or R4 and R5 join to
 form a 3-6 membered, optionally substituted ring structure; Z = O or S; Rx
 is the residue of a natural or unnatural amino acid; L* is a linker moiety
 which is ether, carbonate or ester] or their pharmaceutically-acceptable
 salts were prepared as anti-HIV agents with favorable pharmacokinetic
 properties. Thus, (1S,2S)-N-[cis-2-(6-fluoro-2-(L-
 valyloxy)methoxycarbonyloxy-3-propionylphenyl)cyclopropyl
]-N'-[2-(5-cyanopyridyl)]urea was prepared and showed 70%
 bioavailability of released drug at a dose of 0.027 mmol/kg after 6 h in a
 rat bioavailability assay model.
 AN 2002:696666 HCAPLUS <<LOGINID::20080326>>
 DN 137:217244
 TI Preparation of amino acid-containing non-nucleoside
 reverse transcriptase inhibitors
 IN Zhou, Xiao-xiong; Johansson, Nils-Gunnar; Wahling, Horst; Sund, Christian;
 Salvador, Lourdes; Lindstrom, Stefan; Wallberg, Hans; Sahlberg, Christer
 PA Medivir AB, Swed.
 SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of Appl. No. PCT/SE99/01403.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002128301	A1	20020912	US 2001-927254	20010810 <--
	ZA 9807267	A	19990215	ZA 1998-7267	19980813 <--
	WO 9909031	A1	19990225	WO 1998-SE1467	19980814 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,			
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP	1123935	A2	20010816	EP 2001-103370 19980814 <--
EP	1123935	A3	20010905	
EP	1123935	B1	20050413	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,			
	SI, FI, RO			
NZ	508502	A	20020426	NZ 1998-508502 19980814 <--
CN	1872869	A	20061206	CN 2006-10099722 19980814 <--
ZA	9901148	A	19990812	ZA 1999-1148 19990212 <--
US	6458772	B1	20021001	US 1999-249317 19990212 <--
WO	9941275	A1	19990819	WO 1999-SE194 19990215 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			
	DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,			
	KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,			
	MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,			
	TT, UA, UG, UZ, VN, YU, ZW			
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,			
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,			
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO	2000047561	A1	20000817	WO 1999-SE1403 19990818 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,			
	CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,			
	IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,			
	MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,			
	TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,			
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,			
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU	775578	B2	20040805	AU 2001-35224 20010417 <--
AU	2003200551	A1	20030501	AU 2003-200551 20030218 <--
PRAI	SE 1998-452	A	19980213	<--
	SE 1998-469	A	19980216	<--
	SE 1998-1216	A	19980403	<--
	WO 1998-SE1467	W	19980414	<--
	ZA 1998-7267	A	19980813	<--
	SE 1998-3438	A	19981007	<--
	US 1999-249317	A2	19990212	<--
	WO 1999-SE194	W	19990215	<--
	WO 1999-SE1403	A2	19990818	<--
	SE 1997-2957	A	19970815	<--
	SE 1997-4147	A	19971112	<--
	AU 1998-87548	A3	19980814	<--
	CN 2003-2003157988	A3	19980814	<--
	EP 1998-939041	A3	19980814	<--
	NZ 1998-502837	A1	19980814	<--
	AU 1999-32820	A3	19990215	<--
OS	MARPAT 137:217244			

L20 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Tricycloalkatrienes as non-nucleoside reverse
 transcriptase inhibitors
 GI



AB Title compds. I [R1 = O, S; R2 = (un)substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 = H, alkyl; R4-R7 = H, alkyl, alkenyl, alkynyl, haloalkyl, alkanoyl, haloalkanoyl, alkoxy, haloalkoxy, alkyloxyalkyl, haloalkyloxyalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, cyanoalkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X = (CHR8)nD(CHR8)m; D = NR9, O, S, S(=O), SO2; R8 = H, alkyl, haloalkyl; R9 = H, alkyl; n, m = 0, 1, 2] and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants. Thus, benzothiophene was treated with N2CHCO2Et to give Et cis-1a,6b-dihydro-1H-benzo[b]cyclopropa[d]thiophene-1-carboxylate which was hydrolyzed to the acid and treated with (PhO)2PN3 and 2-amino-6-cyanopyridine to give the urea II. II had ED50 in the XTT assay with wild-type HIV-1IIIB of 2 nM.

AN 2002:695980 HCAPLUS <<LOGINID::20080326>>

DN 137:232544

TI Tricycloalkatrienes as non-nucleoside reverse transcriptase inhibitors

IN Lindstroem, Stefan; Sahlberg, Christer; Wallberg, Hans; Kalyanov, Genaidy; Oden, Lourdes; Naeslund, Lotta

PA Medivir AB, Swed.

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070516	A2	20020912	WO 2002-EP2328	20020304 <--
	WO 2002070516	A3	20030206		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 228990	B	20050311	TW 2002-91103297	20020225	<--
CA 2438524	A1	20020912	CA 2002-2438524	20020304	<--
AU 2002308231	A1	20020919	AU 2002-308231	20020304	<--
AU 2002308231	B2	20070510			
EP 1373261	A2	20040102	EP 2002-748329	20020304	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 1494545	A	20040505	CN 2002-806027	20020304	<--
BR 2002007886	A	20040817	BR 2002-7886	20020304	<--
JP 2004529112	T	20040924	JP 2002-569836	20020304	<--
RU 2281284	C2	20060810	RU 2003-129513	20020304	<--
CN 101081843	A	20071205	CN 2006-10082490	20020304	<--
US 2003069224	A1	20030410	US 2002-92752	20020305	<--
US 6716850	B2	20040406			
US 2003187266	A1	20031002	US 2003-377057	20030228	<--
US 6894177	B2	20050517			
IN 2003DN01281	A	20050527	IN 2003-DN1281	20030813	<--
MX 2003PA08040	A	20040524	MX 2003-PA8040	20030905	<--
HK 1063784	A1	20070309	HK 2004-106555	20040831	<--
US 2005240035	A1	20051027	US 2005-71675	20050302	<--
PRAI SE 2001-733	A	20010305	<--		
CN 2002-806027	A3	20020304	<--		
WO 2002-EP2328	W	20020304	<--		
US 2002-92752	A3	20020305	<--		
US 2003-377057	A3	20030228			
OS	MARPAT 137:232544				

L20 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors

AB Four non-nucleoside reverse transcriptase (RT) inhibitors, 9-Cl-TIBO [(+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4,5,1-jk)(1,4)-benzodiazepin-2(1H)-thione], nevirapine (6,11-dihydro-11-cyclopropyl-4-methyl-dipyrido[2,3-b:2',3'-e]-[1,4]diazepin-6-one), MSA-300 (N-[cis-2-(2-hydroxy-3-acetyl-6-methoxy-phenyl)-cyclopropyl]-N'-(5-chloropyrid-2-yl)-thiourea) and delavirdine {1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methylethylamino)pyridinyl]piperazine} were analyzed for the mode of action of their inhibition of human immunodeficiency virus type 1 (HIV-1) RT in three different assays utilizing a 96-well microtiter plate format, with solid-phase conjugated poly(rA) as template. These were: (i) direct RT assay, for determination of IC₅₀ values of RT inhibitors; (ii) RT template/primer binding inhibition (BIC) assay, for measuring the effect of various substances on the RT activity binding to template/primer; (iii) RT protein ELISA, for measuring RT protein binding to template/primer with a monoclonal antibody reactive against a peptide in the RNase H region. MSA-300 and delavirdine gave the lowest IC₅₀ values, ranging from 0.17 μ M to 0.24 μ M for MSA-300 and from 0.12 μ M to 0.38 μ M for delavirdine, whereas higher IC₅₀ values of approx. 20 μ M were obtained for 9-Cl-TIBO at all primer concns. None of the non-nucleoside concns. None of the non-nucleoside substances had inhibiting effects on the binding of template, primer, or template/primer to RT protein. Their inhibition of RT activity was not due to prevention of RT binding to template/primer. TIBO, nevirapine and delavirdine bound to rt reversibly, and they bound more tightly to RT template/primer ternary than to RT template binary complex. MSA-300 showed a comparatively high affinity for the enzyme. The utility of the three assays in relation to screening and anal. of RT inhibitory

substances is discussed.

AN 1998:205440 HCAPLUS <<LOGINID::20080326>>
DN 128:316856
TI Colorimetric assays for evaluation of the mode of action of human
immunodeficiency virus type 1 non-nucleoside
reverse transcriptase inhibitors
AU Shao, X.; Rytting, A.-S.; Ekstrand, D. H. L.; Vrang, L.; Kallander, C. F.
R.; Gronowitz, J. S.
CS Research Unit Replication Enzymology, Department Medical Genetics, Uppsala
University, Uppsala, 751 23, Swed.
SO Antiviral Chemistry & Chemotherapy (1998), 9(2), 167-176
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT